According to our new research study on “Benign Prostatic Hyperplasic Devices Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product, Procedure Type, End User, and Geography” the market is expected to grow from US$ 2,078.78 million in 2021 to US$ 3,467.31 million by 2028; it is estimated to grow at a CAGR of 7.6% from 2022 to 2028. The rise in the prevalence of benign prostatic hyperplasia amongst men and increasing risk factors is driving the growth of the benign prostatic hyperplasic devices market. Moreover, the rise in investments, funds, and grants for research in BPH treatment is boosting the market growth. However, less awareness about prostate health among men is hampering the market’s growth.
Get Your Free Sample Copy Today | Click Here: https://www.theinsightpartners.com/sample/TIPRE00025704
Benign prostatic hyperplasia (BPH) is a prostate enlargement caused by excessive cell growth in the prostate. BPH is a non-cancerous prostate condition that is not usually fatal. As it is benign, the condition does not involve metastasis to other body parts. BPH is not associated with the risk of prostate cancer; moreover, unless it manifests symptoms, BPH is not considered a health issue. Almost all men are likely to have some prostate growth by age 70. Aging, abdominal obesity, and lack of physical exercise raise the risk of developing BPH.
According to the National Center for Biotechnology Information (NCBI), BPH is one of the most common disorders in older men and the leading cause of lower urinary tract symptoms (LUTS). After the age of 40, the prevalence of BPH rises, reaching a peak of 60% by the age of 90. According to autopsy studies, the histological prevalence of BPH is 8%, 50%, and 80% in the fourth, sixth, and ninth decades of a man’s life, respectively. Old age has also been a risk factor for the onset and progression of clinical BPH in observational studies conducted in Europe, the US, and Asia. According to statistics from the Krimpen and Baltimore Longitudinal Study of Aging, the prostate grows at a rate of 2.0% to 2.5% per year in older men. Continued prostate enlargement is a risk factor for developing LUTS, and larger prostates are associated with a benign prostatic enlargement (BPE), which triggers the risk of developing clinical BPH and urine incontinence.
According to NCBI data, increased adiposity is found to have a positive correlation with prostate volume. In numerous study groups, body weight, body mass index (BMI), and waist circumference have been seen to have a positive correlation with prostate volume. Additionally, epidemiological data shows obesity may raise the necessity of BPH surgery and initiating BPH treatment.
According to the American Journal of Men’s Health (AJMH), in 2019, globally, there were 11.26 million new cases and 1.86 million YLD due to BPH in 2019. The incidence of BPH increased by 105.7%, and YLD increased by 110.6% worldwide during 1990–2019. The absolute incidence and YLD numbers increased considerably worldwide during this period, primarily due to population increase and aging. Therefore, the rising prevalence of benign prostatic hyperplasia and growing risk factors drive the growth of the benign prostatic hyperplasic devices market.
KARL STORZ SE & Co., KG; Richard Wolf GmbH; Olympus Corporation; Urologix, LLC.; Boston Scientific Corporation; Butterfly; TELEFLEX Incorporated; OmniGuide Holdings, Inc.; Convergent Laser Technologies; ProArc; and Olympus Corporation are a few leading companies operating in the benign prostatic hyperplasic devices market.
Based on product, the benign prostatic hyperplasic devices market is segmented into resectoscopes, urology laser, radiofrequency ablation devices, prostatic stents, and implants. Based on procedure type, the market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. Based on end user, the market is segmented into hospitals, clinics, ambulatory surgical centers, and others. By geography, the benign prostatic hyperplasic devices market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, Africa, and the Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Benign Prostatic Hyperplasia Devices, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.
Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : [email protected]
About Author
